Editas Medicine (NASDAQ: EDIT) reported Q1 EPS of ($0.80), $0.19 worse than the analyst estimate of ($0.61).

“We made outstanding progress this quarter building our business for the long term, including forming a strategic alliance with Allergan in ocular diseases, cementing our unmatched intellectual property position with a favorable USPTO decision, and doubling our cash runway,” said Katrine Bosley, President and Chief Executive Officer of Editas Medicine. “These achievements represent significant strides forward in positioning Editas Medicine to execute our vision to build a company that pioneers a broad new category of genomic medicines.”

Cash and cash equivalents at March 31, 2017, were $351.6 million, compared to $185.3 million at December 31, 2016.

For earnings history and earnings-related data on Editas Medicine (EDIT) click here.